Jan. 28 at 4:27 PM
Barclays assumed coverage of
$PTCT ⬆️to Overweight-
$119 from EW-
$68 after initiating coverage of 12 biotech stocks and assuming coverage of 11, with a positive view of the industry.
$BMRN $OTSKY RLFTY SYBX
$QURE $RHHBY WVE TEVA
Barclays says that it likes the setup for the group in 2026—many biotech stocks remain undervalued—expects continued M&A, strong underlying fundamentals, and less of a focus on drug pricing to act as significant tailwinds.
Barclays additionally said, We think PKU could be >
$2B at peak.
We think PKU remains underappreciated and see Sephience beating in 2026 and beyond.
Huntington's Disease (HD) could be meaningful long term and we view regulatory updates as potential
upside drivers this year given low expectations.
